2C-C
2C-C is a psychedelic substance of the substituted phenethylamine class and a member of the 2C-x family.1 It was first synthesized by Cheng and Castagnoli in 19842 and later described in detail by Alexander Shulgin in his 1991 book PiHKAL.citation needed 2C-C is widely regarded as gentler, more relaxed, and more sedating than closely related compounds such as 2C-B, 2C-I, and 2C-E. It remains a lesser-known substance, primarily obtained as a research chemical through online vendors.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Duration
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
Cognitive
The head space of 2C-C is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.
Visual
Distortions
Geometry
The visual geometry of 2C-C can be described as more similar in appearance to that of 4-AcO-DMT or ayahuasca than that of LSD, 2C-B or 2C-I. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large in size, slow and smooth in motion, colourful in scheme, glossy in colour, equally blurred and sharp in their edges and equally rounded and angular in their corners. They give off a contradictory natural and synthetic feel at higher dosages. This substance seems more likely to result in states of Level 8B visual geometry over Level 8A.
Hallucinatory States
2C-C produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics, particularly in comparison to other substances within the phenethylamine family.
Auditory
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Reagent Testing
Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.
Pharmacology
Pharmacodynamics
2C-C acts primarily as a partial agonist at serotonin 5-HT2A receptors (49% intrinsic activity), which is believed to underlie its psychedelic effects. It also shows notable affinity for 5-HT2C and 5-HT2B receptors, with higher intrinsic activity at 5-HT2B (81%), and binds 5-HT1A with approximately 15-fold lower affinity than 5-HT2A. The compound has negligible affinity for monoamine transporters and very weak reuptake inhibition,3 but shows high affinity for rat trace amine-associated receptor 1 (TAAR1), though substantially weaker at mouse TAAR1.citation needed In rodent models, 2C-C has been found to decrease dopamine transporter expression and increase DAT phosphorylation in the nucleus accumbens and medial prefrontal cortex, changes that may elevate extracellular dopamine levels.
Pharmacokinetics
2C-C-specific human pharmacokinetic parameters, including bioavailability, elimination half-life, clearance, and a validated human metabolite profile, have not been established in the reviewed literature.citation needed The frequently cited in-vitro enzyme study found MAO-A and MAO-B involvement in deamination of 2C-B, 2C-I, 2C-D, 2C-E, 2C-T-2, and 2C-T-7; it did not test 2C-C. Its MAO result should therefore be described only as evidence from related 2C compounds, not as measured 2C-C metabolism.4
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Serotonergic psychedelics
Harm Potential
Addiction & Dependence
Psychological
LowWhile anecdotal reports suggest 2C-C is not habit-forming and desire to use may decrease with repeated use, rodent studies have demonstrated reinforcing effects including conditioned place preference and self-administration, suggesting some misuse potential that differs from typical psychedelics.citation needed
Physical
Extremely LowAnecdotal evidence suggests 2C-C is not physically addictive. No withdrawal syndrome has been documented.
Toxicity
Neurotoxicity has been observed at high doses in rodent studies; the relevance to typical human recreational doses is unknown.citation needed
Acute cardiovascular stress including increased blood pressure and heart rate occurs during intoxication, though heart rate elevation may be less pronounced compared to related phenethylamines.
Psychosis Risk
The chance of entering a psychotic or very confused state is relatively low compared to other psychedelics. 2C-C is considered a clear-headed psychedelic overall, though temporary psychosis, paranoia, delusional thinking, and panic attacks remain possible, particularly in individuals with pre-existing mental health conditions.
Seizure Risk
May lower seizure threshold. Contraindicated in individuals with epilepsy or seizure disorders.
History & Culture
2C-C was first synthesized in 1983 by Alice C. Cheng and Neal Castagnoli Jr. at the University of California, San Francisco. The compound was not originally created for its psychoactive properties; rather, it was produced as an intermediate during their investigation of 6-hydroxydopamine analogs…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
1961 Single Convention: 2C-C is not individually scheduled.
1971 Convention on Psychotropic Substances: 2C-C is not individually scheduled.
1988 Convention: 2C-C is not listed in precursor Tables I or II.
By Country
References
Source Pages
Citations
- Dean BV, Stellpflug SJ, Burnett AM, & Engebretsen KM. (June 2013). 2C or Not 2C: Phenethylamine Designer Drug Review. Journal of Medical Toxicology, 9(2), 172–178. https://doi.org/10.1007/s13181-013-0295-x1
- Zamberlan F, Sanz C, Martínez Vivot R, Pallavicini C, Erowid F, Erowid E, & Tagliazucchi E. (2018). The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines. Frontiers in Integrative Neuroscience, 12, Article 54. https://doi.org/10.3389/fnint.2018.000541
- Amy J. Eshleman, Michael J. Forster, Katherine M. Wolfrum, Robert A. Johnson, Aaron Janowsky, & Michael B. Gatch. (March 2014). Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology, 231(5), 875–888. https://doi.org/10.1007/s00213-013-3303-61
- Denis S. Theobald, & Hans H. Maurer. (January 2007). Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochemical Pharmacology, 73(2), 287–297. https://doi.org/10.1016/j.bcp.2006.09.0221
- Young-Jung Kim, Shi-Xun Ma, Kwang-Hyun Hur, Youyoung Lee, Yong-Hyun Ko, Bo-Ram Lee, Seon-Kyung Kim, Su-Jeong Sung, Kyeong-Man Kim, Hyoung-Chun Kim, Seok-Yong Lee, & Choon-Gon Jang. (April 2021). New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents. Archives of Toxicology, 95(4), 1413–1429. https://doi.org/10.1007/s00204-021-02980-x1
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026, sections 1–2 and Schedule classification. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/asmade/2026-05-28/text/original/epub/OEBPS/document_1/document_1.html1
- Criminal Code Regulations 2019, Compilation No. 6 (13 December 2025), Schedule 1 item 53. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2019L00561/2025-12-13/2025-12-13/text/original/epub/OEBPS/document_1/document_1.html1
- Criminal Code Act 1995, Compilation No. 174 (in force 30 June 2026), sections 301.1 and 301.4. legislation.gov.au (n.d.). https://www.legislation.gov.au/C2004A04868/2026-06-30/2026-06-30/text/original/epub/OEBPS/document_2/document_2.html1
- Customs (Prohibited Imports) Regulations 1956, Compilation No. 147 (13 July 2026), regulation 5 and Schedule 4 item 5B. legislation.gov.au (n.d.). https://www.legislation.gov.au/F1996B03651/2026-07-13/2026-07-13/text/original/epub/OEBPS/document_1/document_1.html1
- Neue-Psychoaktive-Substanzen-Verordnung (NPSV), consolidated official text, version 27 August 2026. ris.bka.gv.at (n.d.). https://www.ris.bka.gv.at/GeltendeFassung/Bundesnormen/20007642/NPSV%2c%20Fassung%20vom%2027.08.2026.pdf1
Further Reading
Asanuma et al., 2020 - Neurotoxicity of 2C Series
Eshleman et al., 2014 - Behavioral & Neurochemical Pharmacology
FRANK – Mixing Risks Section
Nervewing: Trip Report - 2C-C (Intranasal)
Nichols D., 2016 - Pharmacology of Psychedelics
Nichols D., 2016 – Pharmacology of Psychedelics
Papaseit et al., 2018 - Acute Effects of 2C-B in Humans
Papaseit et al., 2018 – Acute Effects of 2C-B in Humans
Reddit 2C-C: The Sober Psychedelic
Scarfone et al., 2025 - Toxicodynamic Insights of 2C & NBOMe Drugs
Scarfone et al., 2025 – Toxicodynamic Insights of 2C & NBOMe Drugs
Talk to Frank: 2C Family Drug Facts
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
31 July 2026
Lyrea · Updated the article
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 2C-C article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.